prikaz prve stranice dokumenta Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study
Pristup korisnicima matične ustanove
Znanstveni rad - Prethodno/kratko priopćenje
Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study
Digestive and Liver Disease, 50 (2018), 12; 1362-1365. https://doi.org/10.1016/j.dld.2018.07.042
(STARK Project - Pancreas 2000 Program) Korpela, Taija; Cárdenas-Jaén, Karina; Archibugi, Livia; Poropat, Goran; Maisonneuve, Patrick; Arcidiacono, Paolo Giorgio; De Pretis, Niccolò; Löhr, Matthias; Capurso, Gabriele; de-Madaria, Enrique

Citirajte ovaj rad

Korpela, T., Cárdenas Jaén, K., Archibugi, L., Poropat, G., Maisonneuve, P., Arcidiacono, P. G. ... de Madaria, E. (2018). Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study. Digestive and Liver Disease, 50. (12), 1362-1365. doi: 10.1016/j.dld.2018.07.042

Korpela, Taija, et al. "Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study." Digestive and Liver Disease, vol. 50, br. 12, 2018, str. 1362-1365. https://doi.org/10.1016/j.dld.2018.07.042

Korpela, Taija, Karina Cárdenas Jaén, Livia Archibugi, Goran Poropat, Patrick Maisonneuve, Paolo Giorgio Arcidiacono, Niccolò De Pretis, Matthias Löhr, Gabriele Capurso i Enrique de Madaria. "Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study." Digestive and Liver Disease 50, br. 12 (2018): 1362-1365. https://doi.org/10.1016/j.dld.2018.07.042

Korpela, T., et al. (2018) 'Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study', Digestive and Liver Disease, 50(12), str. 1362-1365. doi: 10.1016/j.dld.2018.07.042

Korpela T, Cárdenas Jaén K, Archibugi L, Poropat G, Maisonneuve P, Arcidiacono PG, i sur.. Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study. Digestive and Liver Disease [Internet]. 12.2018. [pristupljeno 12.11.2024.];50(12):1362-1365. doi: 10.1016/j.dld.2018.07.042

T. Korpela, et al., "Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study", Digestive and Liver Disease, vol. 50, br. 12, str. 1362-1365, Prosinac 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:661675. [Citirano: 12.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:661675
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study
AutorTaija Korpela
AutorKarina Cárdenas-Jaén
AutorLivia Archibugi
AutorGoran Poropat
AutorPatrick Maisonneuve
AutorPaolo Giorgio Arcidiacono
AutorNiccolò De Pretis
AutorMatthias Löhr
AutorGabriele Capurso
AutorEnrique de-Madaria
KolaboracijaSTARK Project - Pancreas 2000 Program
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background: Acute pancreatitis (AP) is the most common complication after endoscopic retrograde cholangiopancreatography (ERCP). Statins have been traditionally associated to an increased risk of AP, however, recent evidence suggests that statins may have a protective role against this disease. Aims: Our primary aim is to investigate whether the use of statins has a protective effect against post-ERCP pancreatitis (PEP). Secondary outcomes are: to evaluate the effect of other drugs on the incidence of PEP; to ascertain the relationship between the use of statins and the severity of PEP; and to evaluate the effect of other risk and protective factors on the incidence of PEP. Methods: STARK is an international multicenter prospective cohort study. Centers from Spain, Italy, Croatia, Finland and Sweden joined this study. The total sample size will include about 1016 patients, which was based on assuming a 5% incidence of PEP among non-statin (NSt) users, a 1-3 ratio of statin (St) and NSt consumers respectively, a 70% decrease in PEP among St consumers, an alpha-error of 0.05 and beta-error of 0.20. All patients aged ≥18 years scheduled for ERCP will be offered to enter the study. Discussion: STARK study will ascertain whether statins, a safe, widely used and inexpensive drug, can modify the incidence of PEP.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Prethodno/kratko priopćenje
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaDigestive and Liver Disease
Brojčani podacivol. 50, br. 12, str. 1362-1365
p-ISSN1590-8658
DOIhttps://doi.org/10.1016/j.dld.2018.07.042
URN:NBNurn:nbn:hr:184:661675
Datum objave publikacije2018-12
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S159086581830879X
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-02-11 12:17:03